1 / 16

How Fixed-Dose Combinations improve the rational use of antiretroviral therapy

How Fixed-Dose Combinations improve the rational use of antiretroviral therapy. MSF experience in 10 countries over 3 years. MSF ARV PROGRAMMES. MSF started HIV programs in low-resource settings in 1997 ART programs started in 2001

chloe
Télécharger la présentation

How Fixed-Dose Combinations improve the rational use of antiretroviral therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. How Fixed-Dose Combinations improve the rational use of antiretroviral therapy MSF experience in 10 countries over 3 years

  2. MSF ARV PROGRAMMES • MSF started HIV programs in low-resource settings in 1997 • ART programs started in 2001 • To date, 39 ART programs in 19 countries in Africa, Asia, Latin America • Over 10,000 patients

  3. BACKGROUND

  4. BACKGROUNDd4T/3TC/NVP • Bidaily fixed-dose • WHO recommended first line • WHO pre-qualified • Most commonly used in MSF programmes

  5. METHODOLOGY • ADHERENCE: pill count • EFFICACY: VL (when available), CD4 • PRICE: Survey of prices among our projects

  6. ADHERENCE

  7. EFFICACY

  8. PRICES • FDC remains the least expensive option compared to originator drugs • Second line drugs are still very expensive

  9. PRICES FIRST LINE

  10. PRICES FIRST LINEINTERNATIONAL OFFERS

  11. PRICES SECOND LINE

  12. CONCLUSIONS • MSF aims to have 80% of patients treated in its projects receiving a triple-FDC regimen as of January 2004. • Currently, 70% of patients and 9 out of the 10 largest MSF projects are using triple FDCs as their first-line treatment

  13. CONCLUSIONS FDCs (d4T/3TC/NVP) are essential tools for scaling up: • effect on adherence and resistance (impossible to take partial dose) • ease of use (2 tablets per day) • distribution advantages • Efficacy • Less expensive

  14. CONCLUSIONS But still many efforts to be done: • Still room for improvement in 1st line (EFV containing FDC, paediatric FDCs) • Second line still very expensive • Need for affordable and simple tools to monitor treatment failure

  15. REFERENCES • Surmounting challenges: Procurement of Antiretroviral Medicines in Low- and Middle-Income Countries (MSF, WHO, UNAIDS, 2003) • Untangling the web of price reductions: A pricing guide for the purchase of ARVs for developing countries (MSF, 2003) • Addison A. Taylor, Omar Shoheiber. Adherence to Antihypertensive Therapy With Fixed-Bose Amlodipine Besylate/Benazepril HCI Versus Comparable Component Based Therapy www.accessmed-msf.org

More Related